Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional etanercept: 1-year results of the COBRA-light open-label, randomised, non-inferiority trial

Annals of the Rheumatic Diseases

Volumn 74, Issue 6, 2015, Pages 1233-1240

  Ter Wee, Marieke M ^a   Den Uyl, Debby ^a   Boers, Maarten ^a,b   Kerstens, Pit ^b,c   Nurmohamed, Mike ^a,b   Van Schaardenburg, Dirkjan ^a,b   Voskuyl, Alexandre E ^a   Lems, Willem F ^a,b   Kvien, Tore K ^d  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Jan Van Breemen Research Institute/Reade   (Netherlands)

^c Westfries Gasthuis   (Netherlands)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; GLUCOCORTICOID; METHOTREXATE; ORAL ANTIDIABETIC AGENT; PREDNISOLONE; SALAZOSULFAPYRIDINE; ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ANEMIA; ARTICLE; BONE DISEASE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DAS44; DEPRESSION; DISEASE ACTIVITY; DISEASE COURSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DUODENUM ULCER; DYSLIPIDEMIA; FEMALE; FIBULA FRACTURE; GASTROINTESTINAL DISEASE; HEALTH ASSESSMENT QUESTIONNAIRE; HEART ARRHYTHMIA; HEART INFARCTION; HIP FRACTURE; HUMAN; HYPERTENSION; INFECTION; INGUINAL HERNIA; LUNG CARCINOMA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MANIA; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PELVIS FRACTURE; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA HEMORRHAGE; RHEUMATOID ARTHRITIS; SHARP VAN DER HEIJDE SCORE; SIDE EFFECT; SKIN DISEASE; SUICIDE ATTEMPT; SYNOVITIS; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; AGED; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL; DRUG COMBINATION; EARLY INTERVENTION;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; EARLY MEDICAL INTERVENTION; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; METHOTREXATE; MIDDLE AGED; PREDNISOLONE; RECEPTORS, TUMOR NECROSIS FACTOR; SULFASALAZINE; TREATMENT OUTCOME;

EID: 84935028399     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-205143     Document Type: Article

References (33)

1. Bakker MF, Jacobs JW, Welsing P.M., et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med 2012; 156:329-39.
2. Knevel R, Tsonaka R, le Cessie S, et al. Comparison of methodologies for analysing the progression of joint destruction in rheumatoid arthritis. Scand J Rheumatol 2013; 42:182-9.
3. Korpela M, Laasonen L, Hannonen P., et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study. Arthritis Rheum 2004; 50:2072-81.
4. Lard LR, Visser H, Speyer I., et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 2001; 111:446-51.
5. Rantalaiho V, Korpela M, Laasonen L., et al. Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial. Arthritis Res Ther 2010; 12: R122.
6. Rantalaiho V, Kautiainen H, Korpela M., et al. Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trial. Ann Rheum Dis 2013. Published Online First 28 Oct 2013. doi:annrheumdis-2013-203497
7. Smolen JS, Aletaha D, Bijlsma J.W., et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69: 631-7.
8. Smolen JS, Landewe R, Breedveld F.C., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014; 73:492-509.
9. Boers M, Verhoeven AC, Markusse H.M., et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997; 350:309-18.
10. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005; 52:3381-90.
11. Landewe RB, Boers M, Verhoeven A.C., et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 2002; 46:347-56.
12. van Tuyl LH, Plass AM, Lems W.F., et al. Why are Dutch rheumatologists reluctant to use the COBRA treatment strategy in early rheumatoid arthritis? Ann Rheum Dis 2007; 66:974-6.
13. van Tuyl LH, Plass AM, Lems W.F., et al. Discordant perspectives of rheumatologists and patients on COBRA combination therapy in rheumatoid arthritis. Rheumatology (Oxford) 2008; 47:1571-6.
14. den Uyl D, ter Wee MM, Boers M, et al. A non-inferiority trial of an attenuated combination strategy ('COBRA-light') compared to the original COBRA strategy: clinical results after 26 weeks. Ann Rheum Dis 2014; 73:1071-8.
15. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38:727-35.
16. Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011; 70:404-13.
17. Prevoo ML, van Gestel AM, van't Hof MA, et al. Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. Br J Rheumatol 1996; 35:1101-5.
18. Siegert CE, Vleming LJ, Vandenbroucke J.P., et al. Measurement of disability in Dutch rheumatoid arthritis patients. Clin Rheumatol 1984; 3:305-9.
19. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Official Journal of the European Communities 2001; 121:34-44.
20. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 2000; 27:261-3.
21. van der Heijde D, Boonen A, Boers M, et al. Reading radiographs in chronological order, in pairs or as single films has important implications for the discriminative power of rheumatoid arthritis clinical trials. Rheumatology (Oxford) 1999; 38:1213-20.
22. Boers M, Kostense PJ. Non-overlapping American College of Rheumatology response rates: a better way to report response in rheumatoid arthritis clinical trials. Arthritis Rheum 2010; 62:3524-7.
23. Piaggio G, Elbourne DR, Altman D.G., et al. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA 2006; 295:1152-60.
24. Piaggio G, Elbourne DR, Pocock S.J., et al. Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA 2012; 308:2594-604.
25. van der Heijde D, van der Helm-van Mil AH, Aletaha D, et al. EULAR definition of erosive disease in light of the 2010 ACR/EULAR rheumatoid arthritis classification criteria. Ann Rheum Dis 2013; 72:479-81.
26. O'Dell JR, Leff R, Paulsen G., et al. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46:1164-70.
27. van Tuyl LH, van der Heijde D, Knol DL, et al. Chronological reading of radiographs in rheumatoid arthritis increases efficiency and does not lead to bias. Ann Rheum Dis 2014; 73:391-5.
28. Vermeer M, Kuper HH, Bernelot Moens HJ, et al. Adherence to a treat-to-target strategy in early rheumatoid arthritis: results of the DREAM remission induction cohort. Arthritis Res Ther 2012; 14:R254.
29. Taylor WJ, Harrison AA, Highton J, et al. Disease Activity Score 28-ESR bears a similar relationship to treatment decisions across different rheumatologists, but misclassification is too frequent to replace physician judgement. Rheumatology (Oxford) 2008; 47:514-18.
30. van Tuyl LH, Lems WF, Voskuyl A.E., et al. Tight control and intensified COBRA combination treatment in early rheumatoid arthritis: 90% remission in a pilot trial. Ann Rheum Dis 2008; 67:1574-7.
31. Sokka T, Haugeberg G, Asikainen J., et al. Similar clinical outcomes in rheumatoid arthritis with more versus less expensive treatment strategies. Observational data from two rheumatology clinics. Clin Exp Rheumatol 2013; 31:409-14.
32. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363:675-81.
33. van Vollenhoven RF, Ernestam S, Geborek P., et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet 2009; 374:459-66.